Who is sponsoring NCT00005995?

NCT00005995 is sponsored by AEterna Zentaris.

What condition does NCT00005995 study?

NCT00005995 studies Kidney Cancer.

What drugs are being tested in NCT00005995?

Interventions: shark cartilage extract AE-941.

What is the status of NCT00005995?

NCT00005995 is currently COMPLETED.

Last reviewed 2013-03-04 · How we verify

AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy

NCT00005995 Phase 3 COMPLETED

RATIONALE: AE-941 may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase III trial to determine the effectiveness of AE-941 in treating patients who have metastatic kidney cancer that has not responded to biological therapy.

Details

Lead sponsor	AEterna Zentaris
Phase	Phase 3
Status	COMPLETED
Start date	2000-10

Conditions

Kidney Cancer

Interventions

shark cartilage extract AE-941

Countries

Canada